Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FB825 in moderate-to-severe allergic asthma
NCT05008965Phase 2Recruiting
- Sponsor
- Oneness Biotech Co., Ltd.
- Start
- Jul 2021
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in allergic asthma comparing FB825 with Placebo (2 arms). Primary endpoint: Occurrence of an exacerbation of asthma at 24 weeks. Started Jul 2021; status: recruiting.
02
Drugs
FB825
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT05008965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05008965.